INS and endometrial cancer: The effect of fasting insulin on overall endometrial cancer strongly attenuated when bioavailable testosterone was included in the model (OR per increase in natural log transformed pmol/L fasting insulin 1.22, 95% CI 0.48 to 3.11, P = 6.78 × 10−1).